Oncopeptides has announced that the first patient has been enrolled in the Immunoglobulin Light Chain (AL) amyloidosis (OP-201) study.
This open-label, phase 1/2 study of melflufen and dexamethasone for patients with AL amyloidosis, following at least one prior line of therapy, is the first study to explore the effect of melflufen outside of multiple myeloma.
“Today we embarked upon the next phase of our journey with melflufen as we initiated patient enrollment in our phase 1/2 AL amyloidosis study,” says Klaas Bakker, CMO of Oncopeptides. “This study will build upon the promising pre-clinical data that we presented at ASH in December of 2019. With a median overall survival of only three and a half years from diagnosis, we hope to see melflufen providing benefit for patients in this clinical setting where new treatment options are desperately needed.”